Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior

Daniel, Laurent; Bouvier, Corinne; Chetaille, Bruno; Gouvernet, Joanny; Luccioni, Aline; Rossi, D.; Lechevallier, É.; Muracciole, Xavier; Coulange, C.; Figarella‐Branger, Dominique

doi:10.1016/s0046-8177(03)00178-3

Cited by 35 publications

(47 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The therapeutic use of anti-NCAM antibodies will be limited, however, by the possibility that metastasis formation may be enhanced through NCAM blocking. NCAM expression tends to be lost in metastatic lesions [18][19][20]23 and, conversely, aberrant expression of L1-CAM in carcinomas was reported to enhance tumor growth and cell migration. According to the herein reported findings, both conditions would augment tumor cell recognition by NK cells.…”

Section: Discussionmentioning

confidence: 99%

“…13 NCAM expression is a marker for neuroendocrine carcinomas of the lung 14,15 and in other organs. 16,17 Aberrant expression has also been detected in renal cell carcinoma, 18 pancreatic adenocarcinoma and b cell tumors, 19,20 in tumors of the salivary gland 21 and gall bladder, 22 and cases of breast and colon carcinoma. 23,24 In line with the adhesive functions of NCAM, low or absent NCAM expression in carcinomas was correlated with a metastatic phenotype and poor survival rates.…”

mentioning

confidence: 99%

“…23,24 In line with the adhesive functions of NCAM, low or absent NCAM expression in carcinomas was correlated with a metastatic phenotype and poor survival rates. [18][19][20]23 NCAM is constitutively expressed by NK and a small subset of T cells with MHC-unrestricted cytotoxicity. 25,26 The role of NCAM expressed by NK cells is controversial.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Blockade of natural killer cell‐mediated lysis by NCAM140 expressed on tumor cells

Jarahian

Watzl

Issa

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Expression of the neural cell adhesion molecule (NCAM) on malignant cells of neuroendocrine, epithelial and hematopoeitic origin has been reported, but its role for tumor cell recognition by the immune system remained uncertain so far. We have studied the cytotoxicity of the natural killer (NK) cell line NK92 and polyclonal NK cells from different donors, against NCAM-deficient and NCAM-transfected tumors. While the pancreatic carcinoma PANC-1 and the glioblastoma T98G showed no enhanced susceptibility to NK lysis after NCAM transfection, de novo NCAM expression in HeLa cervical carcinoma, SHEP neuroblastoma and the multiple myeloma lines RPMI-8226 and LP-1 was associated with significantly decreased lysis by NK cells. Binding of an NCAM-specific monoclonal antibody to NCAM-positive target cells was able to reverse the reduced lysis susceptibility. Conjugate formation of NCAM-expressing tumor cells with NK cells was blocked and could be restored by anti-NCAM. NK cell-expressed NCAM molecules which might engage in homotypic cis-or trans-interactions had no apparent inhibitory function. The known cis-ligands of NCAM, heparan sulfate proteoglycan and L1-CAM, were also not directly involved in NK inhibition. ICAM-1 mRNA and cell surface expression was downmodulated in NCAM-transfected HeLa cells. ICAM-1 is involved in killer cell immune synapse formation. Its downmodulation may therefore contribute to the reduced lysis of NCAM-expressing target cells. We conclude that aberrant expression of NCAM on tumor cells of different histogenetic origin can lead to inhibition of target cell recognition and lysis by NK cells. ' 2007 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Blockade of natural killer cell‐mediated lysis by NCAM140 expressed on tumor cells

Jarahian

Watzl

Issa

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…In majority of the studies, high numbers of immune cells, such as natural killer (NK) cells or CD8+T cells, infiltrating the tumors have been shown to correlate with an improved prognosis for cancer patients (Coca et al, 1997;Deschoolmeester et al, 2010). Elevated CD56+NK cell count has been reported to be associated with a lower risk of progression in prostate cancer (Gannon et al, 2009), and with poor patient outcome in renal cell carcinoma (Daniel et al, 2003). In the present study, analysis of response to treatment and survival, using log rank test after a 4 year follow up period, showed that the patients with low CD56 intratumoral count had better survival than high CD56 intratumoral count (χ2=4.80, p<0.05), with 0.52 fold lower death rate as compared to patients with high CD56 intratumoral count (HR=0.52, 95% CI=0.28-0.93).…”

Section: Discussionmentioning

confidence: 99%

“…In the diagnostic armamentarium, CD56 is a specific histological immune marker for malignant nervous tumors like medulloblastoma and astrocytoma, malignant NK/T-cell lymphomas (NK/T-NHLs), and neuroendocrine carcinoma. Its over expression in malignant cells is linked with an aggressive tumor type, insufficient therapeutic response, and a reduced survival time in different malignancies including lymphoblastic and myeloid leukemias (ALLs/AML), malignant melanoma (Johnson, 1999;Abbott et al, 2004), and different cancers (Pujol et al, 1993;Zoltowska et al, 2001;Daniel et al, 2003Choi et al, 2004Cho et al, 2006;Evans et al, 2006;). It has been reported in different types of epithelial malignancies and sarcomas like Ewings /PNET (McKenzie et al, 1981;Lipinski et al, 1987;Gardner et al, 1998;Farinola et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

Is the Tumor Infiltrating Natural Killer Cell (NK-TILs) Count in Infiltrating Ductal Carcinoma of Breast Prognostically Significant?

Rathore

Goel²,

Makker³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (8), 3757-3761 IntroductionBreast cancer is the most common cause of cancer death in women worldwide (Key et al., 2001), and represents the leading or second most leading cancer in females in India (Ferlay et al., 2010;D'Souza et al., 2013a;2013b). Currently, two major challenges of breast cancer research are; to understand the interrelation between breast cancer and anti-tumor immunity, and to identify candidates whose targeting would contribute to enhance anti-tumor efficiency (Mamessier et al., 2012).The cancer tissue is invaded by a mixed population of immune cells, including T-cells, B-cells, natural killer (NK) cells and macrophages. For a long time NK cells were considered merely as relatively primitive killers, but now they are seen not only as bonafide actors in innate immunity but are also important cells that shape and influence the adaptive immune responses (Poli et al., 2009). NK cells are effector lymphocytes of innate immune system that act by limiting the growth and dissemination of the tumor and are known to have an immunoregulatory role.An established marker for NK cells, CD56, is an AbstractPurpose: The aim of this study was to investigate the prognostic significance of the CD56+NK-TIL count in infiltrating ductal carcinoma (IDC) of breast. Material and Methods: Immunohistochemistry (IHC) was performed using antibodies specific for CD56 on formalin-fixed and paraffin-embedded tissue sections of 175 infiltrating ductal carcinomas (IDC) of breast. Distribution of intratumoral and stromal CD56+NK-TILs was assessed semi-quantitatively. Results: A low intratumoral CD56+count showed significant and inverse associations with tumor grade, stage, and lymph node status, whereas it had significant and direct association with response to treatment indicating good prognosis. These patients had better survival (χ 2 =4.80, p<0.05) and 0.52 fold lower death rate (HR=0.52, 95% CI=0.28-0.93) as compared to patients with high CD56+ intratumoral count. The association of survival was insignificant with low CD56 stromal count as compared to high CD56 stromal count (χ 2 =1.60, p>0.05). Conclusion: To conclude, although NK-TIL count appeared as a significant predictor of prognosis, it alone may not be sufficient for predicting the outcome considering the fact that there exists a crosstalk between NK-TILs and the other immune infiltrating TILs.

show abstract

Biosensors for Neurological Disease

Bell

Kornguth

2007

Handbook of Biosensors and Biochips

View full text Add to dashboard Cite

The diagnosis of neurological disease (ND) traditionally involves the association of specific symptoms in a patient with a clinical examination, consideration of the patient's prior medical history, and clinical laboratory testing (e.g., electroencephalography, electromyography). The decoding of the human genome has made possible the identification of proteomic and genomic biomarkers associated with specific neurological disorders. The identification of multiple biomarkers, including determination of chemical nature and concentration, provides a disease “signature” that is not achievable through testing for any single marker alone. Biomarker signatures can augment conventional clinical evaluation and testing by improving diagnosis, prognosis, monitoring progression, and management of ND. Biomarker signature profiling for a patient can allow for personalized medicine catered to individual need. The need for biosensors in the detection of ND is illustrated by recent events. Two cases of bovine spongiform encephalopathy (BSE) in Canada have cost their beef industry millions of dollars and resulted in precluding shipment of cattle from Canada to the United States. The ability to determine absence of prion disease in live cattle could greatly increase confidence in cattle imports. In a separate example, Tysabri, an immunosuppressant drug effective in lengthening periods of remission in patients with multiple sclerosis (MS), was withdrawn from the market because of occurrence of progressive multifocal leukoencephalopathy (PML) in treated individuals. PML in the treated MS individuals was caused by proliferation of JC virus. The ability to detect JC virus production during treatment with Tysabri could remedy this problem. Biosensors designed to detect analytes indicative of disease are currently available. Ranging from single target detection to more complex multitarget signature profiling, these biosensors are offered for a wide range of disorders. Many focus on the detection of cancer and ND. The platforms used for cancer detection are directly applicable to ND determination because the sensors detect analytes or genetic mutations present in both disease types. Specific products and technologies that are already being used for or can be readily adapted to ND diagnosis, prognosis, and treatment are discussed. A select list of ND‐related biomarkers for current and future study is presented.

show abstract

Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior

Cited by 35 publications

References 26 publications

Blockade of natural killer cell‐mediated lysis by NCAM140 expressed on tumor cells

Blockade of natural killer cell‐mediated lysis by NCAM140 expressed on tumor cells

Is the Tumor Infiltrating Natural Killer Cell (NK-TILs) Count in Infiltrating Ductal Carcinoma of Breast Prognostically Significant?

Biosensors for Neurological Disease

Contact Info

Product

Resources

About